| # | Country | Total Patents | |
|---|---|---|---|
| #1 | EPO (European Patent Office) | 4 | |
| #2 | Canada | 3 | |
| #3 | WIPO (World Intellectual Property Organization) | 3 | |
| #4 | China | 2 | |
| #5 | United States | 1 |
| # | Industry | |
|---|---|---|
| #1 | Pharmaceuticals | |
| #2 | Medical technology | |
| #3 | Foods and drinks |
| # | Technology | |
|---|---|---|
| #1 | Therapeutic chemical compounds | |
| #2 | Medical preparations | |
| #3 | Electrotherapy | |
| #4 | Enzymes |
| # | Name | Total Patents |
|---|---|---|
| #1 | Williams Mark | 11 |
| #2 | Charles Matthew | 6 |
| #3 | Charles Matthew L | 3 |
| #4 | Mark Williams | 2 |
| #5 | Matthew Charles | 2 |
| #6 | Berczi Lorette Istavan | 1 |
| Publication | Filing date | Title |
|---|---|---|
| EP2421554A1 | Tissue kallikrein for the treatment of huntington's disease | |
| CA2759481A1 | Tissue kallikrein for the treatment of schizophrenia and bipolar disorder | |
| WO2010009557A1 | Tissue kallikrein for the treatment of parkinson's disease | |
| US2009162342A1 | Therapeutic uses of glandular kallikrein | |
| EP2182978A1 | Tissue kallikrein for the treatment of diseases associated with amyloid protein |